Lindy Biosciences Teams Up with Novartis for Multi-Target Drug Delivery Innovation
Shots:
- Lindy Biosciences & Novartis have entered into a multitarget exclusive global licensing agreement and strategic partnership to advance self-administered SC injections
- The partnership will employ Lindy Biosciences' microglassification suspension technology to transition Novartis’ select therapeutics into convenient, self-administered SC injections. The tech allows high-concentration biologic delivery, reducing healthcare costs & enhancing patient compliance
- As per the agreement, Lindy Biosciences is entitled to receive $20M upfront, up to $934M regulatory, development and commercial milestones plus net-sales-based single-digit tiered royalties
Ref: Novartis | Image: Novartis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
